Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / September 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Acer Therapeutics Inc. (NASDAQ:AC...
2023-09-01 06:37:00 ET Are Penny Stocks Able to Give You Passive Income in 2023? Penny stocks, typically priced under $5 per share, have become a topic of interest for many investors exploring diverse avenues for generating income. The question often arises: can trading penny stocks ...
2023-08-31 12:41:47 ET Gainers: Acer Therapeutics ( ACER ) +133% . Prime Number Acquisition I Corp. ( NCNC ) +41% . Minim ( MINM ) +29% . Canopy Growth Corporation ( CGC ) +26% . Upland Software ( UPLD ) +23% . Hydrofarm Hold...
2023-08-31 08:29:27 ET More on Acer, Zevra, etc. Zevra Therapeutics, Inc. ( ZVRA ) Q2 2023 Earnings Call Transcript Acer Therapeutics will reacquire OLPRUVA rights from Relief Therapeutics Zevra seeks FDA nod to start trial of KP1077 for sleep disorder narcolepsy...
Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™ , recently approved for the treatment of ure...
2023-08-31 06:32:27 ET Pharmaceutical company Acer Therapeutics ( NASDAQ: ACER ) will reacquire worldwide development, commercialization and economic rights to OLPRUVA (sodium phenylbutyrate) from Relief Therapeutics, excluding the EU, Liechtenstein, San Marin...
NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today ...
2023-08-14 17:02:08 ET Acer Therapeutics press release ( NASDAQ: ACER ): Q2 GAAP EPS of -$0.33. Cash and cash equivalents were $1.6 million as of June 30, 2023, compared to $2.3 million as of December 31, 2022. For further details see: Acer Therapeutics GAAP EPS ...
NEWTON, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financia...
2023-08-02 06:04:22 ET Ares Commercial Real Estate press release ( ACRE ): Q2 GAAP EPS of $0.04. Revenue of $24.99M (-0.6% Y/Y). For further details see: Ares Commercial Real Estate GAAP EPS of $0.04, revenue of $24.99M
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023